The labs that change a decision
A small panel that actually moves your hand — lipids/ApoB, blood pressure, A1c, and a few targeted tests — instead of an expensive dashboard you'll never act on.
The quick answer
Information is only worth it if it changes what you do. Anchor on ApoB or a lipid panel, blood pressure, and A1c/fasting glucose, plus targeted tests when there's a reason (ferritin, vitamin D if symptomatic, thyroid). Skip the vanity panels that generate anxiety and no action.
There’s a version of “getting labs done” that is really just shopping for reassurance — an 80-biomarker panel that produces a beautiful dashboard, three yellow flags of no consequence, and zero changed behavior. The useful version asks one question of every test: if the result comes back high or low, will I do something different? If the answer is no, the test is entertainment.
By that filter, a short list earns its place for nearly every adult:
- ApoB or a lipid panel — because it’s causal in the disease most likely to kill you, and it changes how aggressively you act (see the cardiometabolic tier).
- Blood pressure — technically not a lab, but the same logic: cheap, symptomless, decision-moving.
- A1c or fasting glucose — a read on metabolic drift before it becomes diabetes.
Then a few targeted tests when there’s an actual reason: ferritin if you’re fatigued or a menstruating athlete, vitamin D if you have symptoms or risk factors, thyroid if the picture fits. Cancer screening runs on its own age- and risk-based schedule.
Labs sit below the foundations on this map on purpose. A number doesn’t improve your health — the decision it informs does, and most of those decisions route straight back to sleep, training, nutrition, and the two cardiometabolic levers above.
Evidence, by outcome
Each claim carries its own grade. A strong grade on one outcome doesn't launder a weak one — read them separately.
Screening is valuable when the result changes management; a lipid/ApoB measure and blood pressure meet that bar for essentially every adult. 1 2
The value isn't the number itself but whether it moves a decision. That framing is why this tier sits below the foundations it informs.
Sources
- 1 Review / consensus
LDL cause atherosclerotic cardiovascular disease (EAS Consensus)
European Heart Journal, 2017
Read the source doi.org - 2 Guideline / consensus
2017 ACC/AHA High Blood Pressure Guideline
Hypertension, 2018
Read the source pubmed.ncbi.nlm.nih.gov